A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody
This is a case report of a 57-year-old woman with a history of primary carcinoma of the right breast with metastases to the contralateral axillary lymph node. After a partial response (PR) was induced by high-dose chemotherapy with peripheral blood stem cell transplantation, she underwent mastectomy...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of clinical oncology 2001-11, Vol.31 (11), p.553-556 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 556 |
|---|---|
| container_issue | 11 |
| container_start_page | 553 |
| container_title | Japanese journal of clinical oncology |
| container_volume | 31 |
| creator | Ohta, M Tokuda, Y Suzuki, Y Kubota, M Watanabe, T Fujii, H Sasaki, Y Niwa, T Makuuchi, H Tajima, T |
| description | This is a case report of a 57-year-old woman with a history of primary carcinoma of the right breast with metastases to the contralateral axillary lymph node. After a partial response (PR) was induced by high-dose chemotherapy with peripheral blood stem cell transplantation, she underwent mastectomy with biopsy of the bilateral axillary lymph nodes. Six months after surgery, the patient had multiple lung metastases. She was then treated with five cycles of fluorouracil, mitoxantrone and vindesine. Although a PR was achieved, further chemotherapy could not be given because of cardiac dysfunction. Since immunohistochemical staining for the HER2 gene product was strongly positive on the surface of primary tumor cells, humanized anti-HER2 monoclonal antibody (trastuzumab) was given intravenously. The metastatic lesion decreased in size and finally appeared to be only cicatricial. Twenty-one months after the initial administration of trastuzumab, the pulmonary lesion was excised. The pathological examination revealed no tumor cells in the resected specimen so further treatment was stopped. The relapse-free state has continued for 24 months after the pulmonary resection. |
| doi_str_mv | 10.1093/jjco/hye119 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72387468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72387468</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-a91d11c81914006c61df98fd376edf80839968fbb73b3ddef89e55ee6f1984393</originalsourceid><addsrcrecordid>eNpd0ctLxDAQBvAgiq6Pk3cJHrxINdO0eRxFfIEgiJ5LmkzdLm1Tk1Zd_3q77oLgKUz48THMR8gxsAtgml8uFtZfzpcIoLfIDDKRJ1yksE1mjAuVpApgj-zHuGCM5SqTu2QPQEqeimxG2itqTUT6WQ9zen_znCb-AwN-9QFjrLs3WgY0cZhQZzFQ69u-wQGbJZ1A7zuHjg6ezsfWdPX3NJhuqJNVEG19523jO9P8fpbeLQ_JTmWaiEeb94C83t68XN8nj093D9dXj4nlIh8So8EBWAUaMsaEFeAqrSrHpUBXKaa41kJVZSl5yZ3DSmnMc0RRgVYZ1_yAnK1z--DfR4xD0dbRYtOYDv0YC5lyJTOhJnj6Dy78GKaVY5GCBCaVWqHzNbLBxxiwKvpQtyYsC2DFqoJiVUGxrmDSJ5vIsWzR_dnNzfkP_F6Dsg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217107888</pqid></control><display><type>article</type><title>A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Open Access Titles of Japan</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Ohta, M ; Tokuda, Y ; Suzuki, Y ; Kubota, M ; Watanabe, T ; Fujii, H ; Sasaki, Y ; Niwa, T ; Makuuchi, H ; Tajima, T</creator><creatorcontrib>Ohta, M ; Tokuda, Y ; Suzuki, Y ; Kubota, M ; Watanabe, T ; Fujii, H ; Sasaki, Y ; Niwa, T ; Makuuchi, H ; Tajima, T</creatorcontrib><description>This is a case report of a 57-year-old woman with a history of primary carcinoma of the right breast with metastases to the contralateral axillary lymph node. After a partial response (PR) was induced by high-dose chemotherapy with peripheral blood stem cell transplantation, she underwent mastectomy with biopsy of the bilateral axillary lymph nodes. Six months after surgery, the patient had multiple lung metastases. She was then treated with five cycles of fluorouracil, mitoxantrone and vindesine. Although a PR was achieved, further chemotherapy could not be given because of cardiac dysfunction. Since immunohistochemical staining for the HER2 gene product was strongly positive on the surface of primary tumor cells, humanized anti-HER2 monoclonal antibody (trastuzumab) was given intravenously. The metastatic lesion decreased in size and finally appeared to be only cicatricial. Twenty-one months after the initial administration of trastuzumab, the pulmonary lesion was excised. The pathological examination revealed no tumor cells in the resected specimen so further treatment was stopped. The relapse-free state has continued for 24 months after the pulmonary resection.</description><identifier>ISSN: 0368-2811</identifier><identifier>ISSN: 1465-3621</identifier><identifier>EISSN: 1465-3621</identifier><identifier>DOI: 10.1093/jjco/hye119</identifier><identifier>PMID: 11773264</identifier><language>eng</language><publisher>England: Oxford Publishing Limited (England)</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents - therapeutic use ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Female ; Humans ; Lung Neoplasms - secondary ; Lung Neoplasms - therapy ; Lymphatic Metastasis ; Middle Aged ; Receptor, ErbB-2 - biosynthesis ; Receptor, ErbB-2 - immunology ; Trastuzumab</subject><ispartof>Japanese journal of clinical oncology, 2001-11, Vol.31 (11), p.553-556</ispartof><rights>Copyright Oxford University Press(England) Nov 1, 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-a91d11c81914006c61df98fd376edf80839968fbb73b3ddef89e55ee6f1984393</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11773264$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ohta, M</creatorcontrib><creatorcontrib>Tokuda, Y</creatorcontrib><creatorcontrib>Suzuki, Y</creatorcontrib><creatorcontrib>Kubota, M</creatorcontrib><creatorcontrib>Watanabe, T</creatorcontrib><creatorcontrib>Fujii, H</creatorcontrib><creatorcontrib>Sasaki, Y</creatorcontrib><creatorcontrib>Niwa, T</creatorcontrib><creatorcontrib>Makuuchi, H</creatorcontrib><creatorcontrib>Tajima, T</creatorcontrib><title>A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody</title><title>Japanese journal of clinical oncology</title><addtitle>Jpn J Clin Oncol</addtitle><description>This is a case report of a 57-year-old woman with a history of primary carcinoma of the right breast with metastases to the contralateral axillary lymph node. After a partial response (PR) was induced by high-dose chemotherapy with peripheral blood stem cell transplantation, she underwent mastectomy with biopsy of the bilateral axillary lymph nodes. Six months after surgery, the patient had multiple lung metastases. She was then treated with five cycles of fluorouracil, mitoxantrone and vindesine. Although a PR was achieved, further chemotherapy could not be given because of cardiac dysfunction. Since immunohistochemical staining for the HER2 gene product was strongly positive on the surface of primary tumor cells, humanized anti-HER2 monoclonal antibody (trastuzumab) was given intravenously. The metastatic lesion decreased in size and finally appeared to be only cicatricial. Twenty-one months after the initial administration of trastuzumab, the pulmonary lesion was excised. The pathological examination revealed no tumor cells in the resected specimen so further treatment was stopped. The relapse-free state has continued for 24 months after the pulmonary resection.</description><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - secondary</subject><subject>Lung Neoplasms - therapy</subject><subject>Lymphatic Metastasis</subject><subject>Middle Aged</subject><subject>Receptor, ErbB-2 - biosynthesis</subject><subject>Receptor, ErbB-2 - immunology</subject><subject>Trastuzumab</subject><issn>0368-2811</issn><issn>1465-3621</issn><issn>1465-3621</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0ctLxDAQBvAgiq6Pk3cJHrxINdO0eRxFfIEgiJ5LmkzdLm1Tk1Zd_3q77oLgKUz48THMR8gxsAtgml8uFtZfzpcIoLfIDDKRJ1yksE1mjAuVpApgj-zHuGCM5SqTu2QPQEqeimxG2itqTUT6WQ9zen_znCb-AwN-9QFjrLs3WgY0cZhQZzFQ69u-wQGbJZ1A7zuHjg6ezsfWdPX3NJhuqJNVEG19523jO9P8fpbeLQ_JTmWaiEeb94C83t68XN8nj093D9dXj4nlIh8So8EBWAUaMsaEFeAqrSrHpUBXKaa41kJVZSl5yZ3DSmnMc0RRgVYZ1_yAnK1z--DfR4xD0dbRYtOYDv0YC5lyJTOhJnj6Dy78GKaVY5GCBCaVWqHzNbLBxxiwKvpQtyYsC2DFqoJiVUGxrmDSJ5vIsWzR_dnNzfkP_F6Dsg</recordid><startdate>20011101</startdate><enddate>20011101</enddate><creator>Ohta, M</creator><creator>Tokuda, Y</creator><creator>Suzuki, Y</creator><creator>Kubota, M</creator><creator>Watanabe, T</creator><creator>Fujii, H</creator><creator>Sasaki, Y</creator><creator>Niwa, T</creator><creator>Makuuchi, H</creator><creator>Tajima, T</creator><general>Oxford Publishing Limited (England)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20011101</creationdate><title>A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody</title><author>Ohta, M ; Tokuda, Y ; Suzuki, Y ; Kubota, M ; Watanabe, T ; Fujii, H ; Sasaki, Y ; Niwa, T ; Makuuchi, H ; Tajima, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-a91d11c81914006c61df98fd376edf80839968fbb73b3ddef89e55ee6f1984393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - secondary</topic><topic>Lung Neoplasms - therapy</topic><topic>Lymphatic Metastasis</topic><topic>Middle Aged</topic><topic>Receptor, ErbB-2 - biosynthesis</topic><topic>Receptor, ErbB-2 - immunology</topic><topic>Trastuzumab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ohta, M</creatorcontrib><creatorcontrib>Tokuda, Y</creatorcontrib><creatorcontrib>Suzuki, Y</creatorcontrib><creatorcontrib>Kubota, M</creatorcontrib><creatorcontrib>Watanabe, T</creatorcontrib><creatorcontrib>Fujii, H</creatorcontrib><creatorcontrib>Sasaki, Y</creatorcontrib><creatorcontrib>Niwa, T</creatorcontrib><creatorcontrib>Makuuchi, H</creatorcontrib><creatorcontrib>Tajima, T</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ohta, M</au><au>Tokuda, Y</au><au>Suzuki, Y</au><au>Kubota, M</au><au>Watanabe, T</au><au>Fujii, H</au><au>Sasaki, Y</au><au>Niwa, T</au><au>Makuuchi, H</au><au>Tajima, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody</atitle><jtitle>Japanese journal of clinical oncology</jtitle><addtitle>Jpn J Clin Oncol</addtitle><date>2001-11-01</date><risdate>2001</risdate><volume>31</volume><issue>11</issue><spage>553</spage><epage>556</epage><pages>553-556</pages><issn>0368-2811</issn><issn>1465-3621</issn><eissn>1465-3621</eissn><abstract>This is a case report of a 57-year-old woman with a history of primary carcinoma of the right breast with metastases to the contralateral axillary lymph node. After a partial response (PR) was induced by high-dose chemotherapy with peripheral blood stem cell transplantation, she underwent mastectomy with biopsy of the bilateral axillary lymph nodes. Six months after surgery, the patient had multiple lung metastases. She was then treated with five cycles of fluorouracil, mitoxantrone and vindesine. Although a PR was achieved, further chemotherapy could not be given because of cardiac dysfunction. Since immunohistochemical staining for the HER2 gene product was strongly positive on the surface of primary tumor cells, humanized anti-HER2 monoclonal antibody (trastuzumab) was given intravenously. The metastatic lesion decreased in size and finally appeared to be only cicatricial. Twenty-one months after the initial administration of trastuzumab, the pulmonary lesion was excised. The pathological examination revealed no tumor cells in the resected specimen so further treatment was stopped. The relapse-free state has continued for 24 months after the pulmonary resection.</abstract><cop>England</cop><pub>Oxford Publishing Limited (England)</pub><pmid>11773264</pmid><doi>10.1093/jjco/hye119</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0368-2811 |
| ispartof | Japanese journal of clinical oncology, 2001-11, Vol.31 (11), p.553-556 |
| issn | 0368-2811 1465-3621 1465-3621 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72387468 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Open Access Titles of Japan; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Agents - therapeutic use Breast Neoplasms - metabolism Breast Neoplasms - pathology Breast Neoplasms - therapy Female Humans Lung Neoplasms - secondary Lung Neoplasms - therapy Lymphatic Metastasis Middle Aged Receptor, ErbB-2 - biosynthesis Receptor, ErbB-2 - immunology Trastuzumab |
| title | A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T18%3A15%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20case%20with%20HER2-overexpressing%20breast%20cancer%20completely%20responded%20to%20humanized%20anti-HER2%20monoclonal%20antibody&rft.jtitle=Japanese%20journal%20of%20clinical%20oncology&rft.au=Ohta,%20M&rft.date=2001-11-01&rft.volume=31&rft.issue=11&rft.spage=553&rft.epage=556&rft.pages=553-556&rft.issn=0368-2811&rft.eissn=1465-3621&rft_id=info:doi/10.1093/jjco/hye119&rft_dat=%3Cproquest_cross%3E72387468%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217107888&rft_id=info:pmid/11773264&rfr_iscdi=true |